Mater Hospital Sydney

North Sydney 2060

0 studies enrolling now · 1 studies all time

What they study most

Breast Cancer, TNBC - Triple-Negative Breast Cancer

Studies at this site

• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) — Completed